GLP-1 drugs — the class behind semaglutide and tirzepatide — may do more than shed pounds. Recent studies suggest they could prevent cancer and slow its progression, though researchers say they don’t yet know why.
Weight loss itself has long been tied to lower cancer risk, and that connection isn’t new. What’s catching scientists’ attention is the possibility that GLP-1s work through separate brain and metabolic pathways that have nothing to do with the number on a scale — meaning the drugs might be doing something to cancer biology that weight loss alone can’t explain.
The findings were reported Monday, June 9, 2026, by NPR. No specific trial data, patient counts, or lead researchers were named in the initial report.
How the drugs might act on those pathways isn’t settled. Researchers are still working to untangle whether the cancer signal comes from the weight loss, the drug itself, or some combination — and that distinction matters for how the medications might eventually be used in oncology.
Reported by NPR. Read the original report.
